A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

NCT00160524 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

596

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

BIOLOGICAL: Certolizumab Pegol (CDP870)

Sponsor

UCB Pharma SA